The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients

References

• TonelliMSacksFPfefferMGaoZCurhanGRelation between serum phosphate level and cardiovascular event rate in people with coronary diseaseCirculation20051121726272633 Erratum in: Circulation2007;116(23):e55616246962
   PubMed Web of Science ®Google Scholar
• ZhengCMLuKCWuCCHsuYHLinYFAssociation of serum phosphate and related factors in ESRD-related vascular calcificationInt J Nephrol2011 Epub May 25, 2011
   Google Scholar
• NakaiSAkibaTKazamaJEffects of serum calcium, phosphorus, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in JapanTher Apher Dial2008121495418257812
   PubMed Web of Science ®Google Scholar
• BlockGAKlassenPSLazarusJMOfsthunNLowrieEGChertowGMMineral metabolism, mortality, and morbidity in maintenance hemodialysisJ Am Soc Nephrol20041582208221815284307
   PubMed Web of Science ®Google Scholar
• KuriharaSMarumoFAluminum and iron deposition in dialysis patientsNihon Rinsho199250Suppl905910 Japanese1578787
   PubMedGoogle Scholar
• ChertowGMBurkeSKRaggiPfor Treat to Goal Working GroupSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney Int200262124525212081584
   PubMed Web of Science ®Google Scholar
• OkaYMiyazakiMTakatsuSSevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosageTher Apher Dial200711210711317381531
   PubMed Web of Science ®Google Scholar
• PaiABSheplerBMComparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implicationsPharmacotherapy200929555456119397463
   PubMed Web of Science ®Google Scholar
• AlbaajFHutchisonAJLanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patientsExpert Opin Pharmacother20056231932815757427
   PubMed Web of Science ®Google Scholar
• DammentSJShenVAssessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic ratsClin Nephrol200563212713715730055
   PubMed Web of Science ®Google Scholar
• JoyMSFinnWFfor LAM-302 Study GroupRandomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemiaAm J Kidney Dis20034219610712830461
   PubMed Web of Science ®Google Scholar
• ShigematsuTfor Lanthanum Carbonate Research GroupLanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysisTher Apher Dial2008121556118257813
   PubMed Web of Science ®Google Scholar
• KawanishiHIshidaMIshizakiMLanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPDPerit Dial Int200828667367518981401
   PubMed Web of Science ®Google Scholar
• ShigematsuTKonoTSatohKPhosphate overload accelerates vascular calcium deposition in end-stage renal disease patientsNephrol Dial Transplant200318Suppl 3iii86iii8912771310
   PubMedGoogle Scholar
• ShigematsuTfor Lanthanum Carbonate Research GroupMulticenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemiaClin Nephrol200870540441019000540
   PubMed Web of Science ®Google Scholar
• SpragueSMRossEANathSDZhangPPrattRDKrauseRLanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover studyClin Nephrol200972425225819825330
   PubMed Web of Science ®Google Scholar
• HutchisonAJBarnettMEKrauseRKwanJTSiamiGAfor SPD405-309 Lanthanum Study GroupLong-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatmentNephron Clin Pract20081101c15c23 Erratum in: Nephron Clin Pract2008;110(1):c2318667837
   PubMed Web of Science ®Google Scholar
• HutchisonAJBarnettMEKrauseRJSiamiGAfor Lanthanum Carbonate Study GroupLanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysisClin Nephrol200971328629519281739
   PubMed Web of Science ®Google Scholar
• FinnWFJoyMSfor LAM-308 Study GroupA long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysisCurr Med Res Opin200521565766415969865
   PubMed Web of Science ®Google Scholar
• SpragueSMA comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonateCurr Med Res Opin200723123167317517991307
   PubMed Web of Science ®Google Scholar
• ShigematsuTfor Lanthanum Carbonate Research GroupThree-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patientsClin Exp Nephrol201014658959720814807
   PubMed Web of Science ®Google Scholar
• D’HaesePCSpasovskiGBSikoleAA multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patientsKidney Int Suppl200385S73S7812753271
   PubMed Web of Science ®Google Scholar
• MallucheHHSiamiGASwanepoelCImprovements in renal osteodystrophy in patients treated with lanthanum carbonate for two yearsClin Nephrol200870428429518826853
   PubMed Web of Science ®Google Scholar
• ShigematsuTTokumotoANakaokaAArisakaHEffect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemiaTher Apher Dial201115217618421426511
   PubMed Web of Science ®Google Scholar
• BehetsGJDamsGVercauterenSRDoes the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?J Am Soc Nephrol20041582219222815284308
   PubMed Web of Science ®Google Scholar
• AltmannPBarnettMEFinnWFfor SPD405-307 Lanthanum Carbonate Study GroupCognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapyKidney Int200771325225917035945
   PubMed Web of Science ®Google Scholar
• SlatopolskyELiapisHFinchJProgressive accumulation of lanthanum in the liver of normal and uremic ratsKidney Int20056862809281316316357
   PubMed Web of Science ®Google Scholar
• Ben-DovIZPappoOSklair-LevyMLanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic ratsNephrol Dial Transplant200722236236817090605
   PubMed Web of Science ®Google Scholar
• BervoetsAJBehetsGJSchryversDHepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failureKidney Int200975438939819052535
   PubMed Web of Science ®Google Scholar
• GotoSKomabaHMoriwakiKClinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in JapanClin J Am Soc Nephrol2011661375138421551021
   PubMed Web of Science ®Google Scholar
• GutiérrezOMMannstadtMIsakovaTFibroblast growth factor 23 and mortality among patients undergoing hemodialysisN Engl J Med2008359658459218687639
   PubMed Web of Science ®Google Scholar
• ShigematsuTNegiSfor the COLC Research GroupCombined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study)Nephrol Dial Transplant20122731050105421771755
   PubMed Web of Science ®Google Scholar
• Gonzalez-ParraEGonzalez-CasausMLGalánALanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patientsNephrol Dial Transplant20112682567257121436379
   PubMed Web of Science ®Google Scholar
• HayashiHMachidaMSekineTYamaguchiHKiriyamaTKumitaSBeam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysisJpn J Radiol201028432232420512553
   PubMed Web of Science ®Google Scholar
• FürstenbergABuscombeJDavenportAOverestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney diseaseAm J Nephrol201032542543120861616
   PubMed Web of Science ®Google Scholar
• ChanMRYevzlinASHinshawMJafferyJBCalciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapyWMJ2008107733533819180873
   PubMedGoogle Scholar
• MuneSShibataMHatamuraIMechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosisClin Exp Nephrol200913657157719655218
   PubMed Web of Science ®Google Scholar
• ToussaintNDLauKKPolkinghorneKRKerrPGAttenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trialNephrology (Carlton)201116329029821342323
   PubMed Web of Science ®Google Scholar